TRDA
NASDAQ · Biotechnology
Entrada Therapeutics Inc
$7.33
+0.26 (+3.68%)
Open$6.64
Previous Close$7.07
Day High$7.41
Day Low$6.64
52W High$16.45
52W Low$4.93
Volume—
Avg Volume231.9K
Market Cap275.24M
P/E Ratio—
EPS$-4.00
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+146.1% upside
Current
$7.33
$7.33
Target
$18.04
$18.04
$12.20
$18.04 avg
$27.27
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 24.87M | 42.90M | 41.05M |
| Net Income | -140,638,624 | 8.98M | 10.98M |
| Profit Margin | -565.5% | 20.9% | 26.8% |
| EBITDA | -150,474,342 | 15.57M | 16.71M |
| Free Cash Flow | — | 11.03M | 8.57M |
| Rev Growth | — | +8.9% | +15.8% |
| Debt/Equity | — | 0.18 | 0.20 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |